Compare Axon Enterprise Inc (AXON) vs CVS Health Corp (CVS) Price & Performance

Axon Enterprise (AXON) trades at $571.01, up 9.29% with strong momentum following Q2 2026 results showing 35% revenue growth and 10 consecutive quarters above 30% expansion. Technical indicators show bullish moving averages with current price near resistance at $587. The company maintains dominant positioning in public safety technology with accelerating AI and counter-drone business segments driving future growth potential.

Axon presents compelling growth prospects with raised 2026 revenue guidance of 32-34% and expanding software ecosystem, though elevated valuations (P/E 248) and margin pressures from service mix shifts warrant caution. Analyst consensus remains strongly bullish with $685 price target representing 20% upside potential from current levels.

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.